BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37550760)

  • 1. The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial.
    Amini S; Golshani M; Moslehi M; Hajiahmadi S; Askari G; Iraj B; Bagherniya M
    Trials; 2023 Aug; 24(1):501. PubMed ID: 37550760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 3. Differentiated thyroid cancer and selenium supplements for protection of salivary glands from
    Mazokopakis E
    Hell J Nucl Med; 2018; 21(1):83-84. PubMed ID: 29550852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasonographic Features of Salivary Glands after Radioiodine Therapy in Patients with Thyroid Cancer.
    Tsur N; Avishai G; Alkan U; Hod R; Shpitzer T; Bitton E; Gilat H
    Laryngoscope; 2023 May; 133(5):1271-1275. PubMed ID: 36354236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
    Ma C; Xie J; Chen Q; Wang G; Zuo S
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007956. PubMed ID: 19821441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Auttara-Atthakorn A; Sungmala J; Anothaisintawee T; Reutrakul S; Sriphrapradang C
    Front Endocrinol (Lausanne); 2022; 13():960265. PubMed ID: 36105397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer.
    Son H; Lee SM; Yoon RG; Lee H; Lee I; Kim S; Chung WY; Lee JW
    Hell J Nucl Med; 2017; 20(1):62-70. PubMed ID: 28315910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial.
    Jayarajah U; Wijekoon M; Seneviratne SA
    Trials; 2020 Sep; 21(1):812. PubMed ID: 32993815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Xerostomia and Ultrasonographic Features of the Major Salivary Glands After Radioactive Iodine Ablation for Papillary Thyroid Carcinoma.
    Soo Roh S; Wook Kim D; Jin Baek H
    AJR Am J Roentgenol; 2016 Nov; 207(5):1077-1081. PubMed ID: 27504709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
    Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M
    J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose.
    Lee HN; An JY; Lee KM; Kim EJ; Choi WS; Kim DY
    Clin Imaging; 2015; 39(3):396-400. PubMed ID: 25630229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Parotid and Submandibular Glands With Shear Wave Elastography Following Radioactive Iodine Therapy for Papillary Thyroid Carcinoma.
    Rahatli FK; Turnaoglu H; Iyidir OT; Kirnap NG; Haberal KM; Aydın E; Uslu N
    J Ultrasound Med; 2019 Feb; 38(2):357-362. PubMed ID: 30027680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
    Torun N; Muratli A; Serim BD; Ergulen A; Altun GD
    Curr Med Imaging Rev; 2019; 15(4):395-404. PubMed ID: 31989909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of radioactive iodine treatment of thyroid carcinoma.
    Lee SL
    J Natl Compr Canc Netw; 2010 Nov; 8(11):1277-86; quiz 1287. PubMed ID: 21081784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial.
    Sawka AM; Straus S; Brierley JD; Tsang RW; Rotstein L; Rodin G; Gafni A; Ezzat S; Thabane L; Thorpe KE; Goldstein DP
    Trials; 2010 Jul; 11():81. PubMed ID: 20659341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.